Fennec appoints Jeffrey Hackman as CEO, succeeding Rostislav Raykov

FENNEC PHARMACEUTICALS INC.

Hackman named CEO and director effective August 16, 2024; Raykov steps down after 15 years, remains on board.
Hackman's initial salary $550,000, target bonus 50% of salary, granted 400,000 options vesting over three years.
Raykov enters separation agreement; acceleration of 292,359 options at weighted avg price $7.50; RSUs intact through April 2027.
Hackman brings 30+ years commercial oncology experience; previously led U.S. operations at Sigma Tau, Baxalta, Shire, EUSA Pharma.
Appointment comes as company expands PEDMARK use for cisplatin-induced ototoxicity in pediatric and AYA patients.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Rostislav Raykov

Chief Executive Officer

FENC · FENNEC PHARMACEUTICALS INC.

Successor: Jeffrey S. Hackman
Filed: August 7, 2024, 7:59 PM ET

the Company announced the departure of Rostislav Raykov from his position as the Company’s Chief Executive Officer

Appointed

Jeffrey S. Hackman

Chief Executive Officer

FENC · FENNEC PHARMACEUTICALS INC.

Effective: 2024-08-05
Filed: August 7, 2024, 7:59 PM ET

the Company announced the appointment of Jeffrey S. Hackman as CEO and a member of the Board.

Appointed

Jeffrey S. Hackman

Director

FENC · FENNEC PHARMACEUTICALS INC.

Effective: 2024-08-05
Filed: August 7, 2024, 7:59 PM ET

the Company announced the appointment of Jeffrey S. Hackman as CEO and a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rostislav Raykov departed as Chief Executive Officer at FENNEC PHARMACEUTICALS INC..

Action: depart
Role: Chief Executive Officer

Exact text from the filing

the Company announced the departure of Rostislav Raykov from his position as the Company’s Chief Executive Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey S. Hackman was appointed as Chief Executive Officer at FENNEC PHARMACEUTICALS INC..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

the Company announced the appointment of Jeffrey S. Hackman as CEO and a member of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey S. Hackman was appointed as Director at FENNEC PHARMACEUTICALS INC..

Action: appointed
Role: Director

Exact text from the filing

the Company announced the appointment of Jeffrey S. Hackman as CEO and a member of the Board.

View on SEC.gov

FENNEC PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-086369

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.